Comparison of clinical characteristics between rifampin-dependent and rifampin- resistant patients with pulmonary tuberculosis.
- Author:
Yan LI
1
;
Shouyong TAN
;
Chunming LUO
;
Yanqiong LI
;
Hongjuan QIN
;
Zhiyu FENG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antitubercular Agents; pharmacology; therapeutic use; Female; Humans; Male; Middle Aged; Mycobacterium tuberculosis; drug effects; Rifampin; pharmacology; therapeutic use; Tuberculosis, Multidrug-Resistant; drug therapy; microbiology; Tuberculosis, Pulmonary; drug therapy; microbiology; Young Adult
- From: Journal of Southern Medical University 2013;33(2):287-289
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the clinical characteristics of rifampin-dependent (R-dependent Mycobacterium tuberculosis) and rifampin-resistant (R-resistant Mycobacterium tuberculosis) patients with pulmonary tuberculosis.
METHODSThe clinical data including the demographic data, age groups, course of disease, history of chemotherapy with anti-TB drugs, and results of drug susceptibility test were collected from 61 cases of R-dependent pulmonary tuberculosis and 148 cases of R-resistant pulmonary tuberculosis treated between October, 2008 and January, 2012.
RESULTSMost of the R-dependent and R-resistant patients were between 30 and 44 years of age. The R-dependent patients included 12 receiving the first treatment patients and 49 with previous treatments, and the R-resistant patients included 11 without and 137 with previous treatments. The multi-drug resistant rate was 80.3% in R-dependent group, as compared to 92.6% in R-resistant group.
CONCLUSIONMost of the patients infected with R-dependent Mycobacterium tuberculosis are young or middle-aged, often having serious disease conditions. Detecting rifampin dependence is important for patients with initial treatment failure. Multi-drug resistance therapy guideline should be applied to patients infected with R-dependent Mycobacterium tuberculosis to improve the cure rate.
